Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Nur Nicholson Sells 2,145 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,145 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $29.96, for a total transaction of $64,264.20. Following the transaction, the insider now owns 52,011 shares in the company, valued at approximately $1,558,249.56. This trade represents a 3.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nur Nicholson also recently made the following trade(s):

• On Wednesday, January 22nd, Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total value of $120,137.64.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock opened at $30.76 on Friday. The stock has a market capitalization of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $71.90. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm’s 50-day moving average is $31.95 and its two-hundred day moving average is $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue was up 78.3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.17) EPS. Equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

APLS has been the subject of several recent analyst reports. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Oppenheimer decreased their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler cut their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Finally, Robert W. Baird decreased their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.71.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. Braidwell LP raised its stake in Apellis Pharmaceuticals by 410.8% during the third quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after purchasing an additional 2,513,383 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares during the period. JPMorgan Chase & Co. boosted its holdings in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Apellis Pharmaceuticals during the third quarter worth about $6,226,000. Finally, AQR Capital Management LLC raised its holdings in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after purchasing an additional 190,420 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).